Brand Name : Scapho
Composition : Secukinumab
Strength availability : 150mg
Manufactured by : Novartis India Ltd
Form : injection
Pack : 150mg in 1 vial
for MORE INFORMATION !!!
Secukinumab belongs to monoclonal antibody which is a protein which recognises and connect to an inflammatory protein called Interleukin 17A (IL-17A). In patients with psoriatic arthritis and ankylosing spondylitis, the body’s immune system produces an increased amount of IL-17A which causes the symptoms such as swollen and painful joints
Scapho is a prescription drugs which is used under proper guidance of medical oncologist
Scapho indicated for the treatment of following condition
Starting dose: given 300 mg SC at weeks 0, 1, 2, 3, and 4
initially at week 8, administer 300 mg SC once monthly
For some patientsmay be acceptable containing dose of 150 mg
Psoriatic Arthritis : Indicated for adults with active psoriatic arthritis
Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection
Scapho with loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without loading dose administrated 150 mg SC q4wk.
Consider a dosage of 300 mg, if a patient continues to have active psoriatic arthritis
May be administered with or without methotrexate.
Given with or without a loading dosage by SC injection
Scapho with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter
Scapho without a loading dose is administrated150 mg SC q4wk
Secukinumab mechanism as Interleukin-17A (IL-17A) is a cornerstone cytokine (messenger protein) contains in the development of psoriasis and
is found in peak concentrations in psoriasis plaques.
Secukinumab consist of human IgG1 monoclonal antibody which selectively binds to IL-17A, rapidly prohibiting its pro-inflammatory effects.
Maximum plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days
Volume of distribution is 7.1 – 8.6 (IV administration)
The drug scapho is Metabolized via intracellular catabolism.
Scapho has half-life is 22-31 days
Scapho may have high risk of infections; use with caution in patients with chronic infection or a history of recurrent infection
Before to initiation of scapho,start with anti-TB therapy in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed
May infuriate Crohn disease
Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment
Live vaccinations combination with scapho should be avoided
CYP450 substrates concomitant use with scapho injection may altered by increased levels of certain cytokines.
Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients
Store the drug at 2℃ to 8℃.
In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them.
thereby missed dose should be avoid and follow the regular dosing schedule.
• URT infection
• Oral herpes